Stop Atherosclerosis in Native Diabetics Study (SANDS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACE inhibitors; Alpha adrenergic receptor antagonists; Angiotensin receptor antagonists; Antihypertensives; Beta 2 adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Ezetimibe; Fenofibrate; HMG-CoA reductase inhibitors; Hydrochlorothiazide; Niacin; Vasodilators
Indications Atherosclerosis; Cardiovascular disorders; Diabetic angiopathies; Hypertension; Lipid metabolism disorders; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms SANDS

05 Feb 2009 Biomarkers information updated
20 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
08 Oct 2005 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com